Cryolife Inc. soared 14.1% on Tuesday with news that an analyst at Piper Jaffray & Co. reiterated his “overweight” rating on the stock, indicating that it is a better value for its price than industry peers.

The reiteration comes a day after Cryolife reported Q2 2016 revenue of $47.1 million and $0.13 cents in earnings per share respectively. This beat the Zacks Consensus Estimate of $0.02 in earnings per share and $45 million in revenue.

Based in Kennesaw, GA, Cryolife develops and commercializes implantable living human tissues for use in cardiovascular, vascular, and orthopedic surgeries throughout the U.S. and Canada.

Analysts have not revised any estimates for Cryolife in the last 60 days. Estimates for this quarter stand at $0.05 in earnings per share, with estimates for this fiscal year at $0.21 in earnings per share.

Cryolife’s recent earnings beat represents a whopping 550% surprise, bringing their average surprise over the last 4 quarters to 502.50%. As you can see in this chart, Cryolife has beaten earnings estimates consistently over the last few years.

CRYOLIFE INC Price and EPS Surprise

CRYOLIFE INC Price and EPS Surprise | CRYOLIFE INC Quote

The MED INSTRUMENTS industry, which Cryolife is a part of, is currently ranked 67/265 amongst all industries, which puts it in the top 25% in the Zacks Industry Rank.

Cryolife currently sits at a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>